Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-GASTRIC01: AZD0901 vs investigator's choice in CLDN18.2-positive advanced gastric/GEJ cancer
jRCT2031240373Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Randomised trial of sonesitatug vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival (PFS) in all randomized participants. Started May 2024; status: active, not recruiting.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031240373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240373.